We have previously identified PRIMA-1, a low molecular weight compound that restores the transcriptional transactivation function to mutant p53 and induction of apoptosis. To explore the molecular mechanism for PRIMA-1-induced mutant p53-dependent apoptosis, we examined the intracellular distribution of mutant p53 upon treatment with PRIMA-1 MET by immunofluorescence staining. We found that PRIMA-1 MET induced nucleolar translocation of mutant p53 and the promyelocytic leukemia (PML) nuclear body-associated proteins PML, CBP and Hsp70. Levels of Hsp70 were significantly enhanced by PRIMA-1 MET treatment. PRIMA-Dead, a compound structurally related to PRIMA-1 but unable to induce mutant p53-dependent apoptosis, failed to induce nucleolar translocation of mutant p53. Our results suggest that redistribution of mutant p53 to nucleoli plays a role in PRIMA-1-induced apoptosis. Oncogene (2007) 26, 982-992.
Introduction
The tumor suppressor p53 induces cell-cycle arrest, apoptosis and/or senescence in response to cellular stress such as DNA damage, oncogene activation, hypoxia and telomere erosion (for a review, see Vousden and Lu (2002) ). p53 is a transcription factor that binds DNA and activates transcription of target genes including p21, MDM2, GADD45, Bax and PUMA. The critical role of p53 as tumor suppressor is illustrated by the fact that p53 is mutated in more than 50% of human tumors, including most if not all tumor types (Olivier et al., 2002) . The great majority of p53 mutations are missense mutations in the DNA-binding core domain, resulting in inactivation or impairment of p53 DNA binding and transcriptional activity. Point mutant p53 is often expressed at high levels in tumor cells, due to failure to transactivate the p53 antagonist MDM2 which targets p53 for proteasome-mediated degradation (reviewed by Vousden and Lu (2002) ). Mutant p53-carrying tumors are usually more resistant to currently used anticancer therapy. Therefore, reconstitution of wild-type p53 function in human tumors is an important therapeutic goal. Several low molecular weight compounds that reactivate mutant p53 have been identified, for example, CP-31398 (Foster et al., 1999) , PRIMA-1 (Bykov et al., 2002a, b) and MIRA-1 (Bykov et al., 2005a) . PRIMA-1 restores wild-type conformation and DNA binding to mutant p53 proteins and induces apoptosis in human tumor cells in a mutant p53-dependent manner. PRIMA-1 MET , a methylated form of PRIMA-1, is even more potent in inducing mutant p53-dependent apoptosis than PRIMA-1 itself (Bykov et al., 2005b) .
The promyelocytic leukemia nuclear body (PMLNBs, also termed Kremer bodies, PML oncogenic domains, PODs, nuclear domain 10, ND10, NBs or nuclear dots, NDs) are dynamic macromolecular structures dependent on the tumor suppressor PML for its formation. PML was originally identified as the fusion partner with the retinoic acid receptor RARalpha in leukemic blasts from patients suffering from acute promyelocytic leukemia (APL), leading to disrupted PML-NBs (Melnick and Licht, 1999) . Accumulating evidence indicates that PML-NBs play regulatory roles in cellular processes such as cell growth (Fagioli et al., 1998; Cohen et al., 2001) , chromatin remodeling (Amin et al., 2001) , cellular differentiation (Drouin et al., 2001) , protein degradation (Lallemand-Breitenbach et al., 2001) , transcriptional regulation (Li et al., 2000; Zhong et al., 2000) , antiviral response (Everett, 2001; Regad and Chelbi-Alix, 2001 ), cellular senescence (Ferbeyre et al., 2000; Pearson et al., 2000; Bischof et al., 2002; Langley et al., 2002) , tumor suppression (reviewed by Salomoni and Pandolfi (2002) ), DNA repair (Bischof et al., 2001; Carbone et al., 2002) and apoptosis (Wang et al., 1998; Fogal et al., 2000; Guo et al., 2000; D'Orazi et al., 2002; Hofmann et al., 2002) .
To date more than 40 different cellular proteins and a number of viral proteins have been found to colocalize with PML in the PML-NBs. Several reports indicate that PML-NBs and some of its residents might regulate apoptosis by serving as modification or activation platforms for p53 and by regulating the subcellular availability of p53 and other apoptotic regulators. Multiple p53-regulating factors have been found within or in association with PML-NBs; PML (Ferbeyre et al., 2000; Fogal et al., 2000; Guo et al., 2000) , CREBbinding protein (CBP) (Pearson et al., 2000) , homeodomain-interacting protein kinase 2 (HIPK2) (D'Orazi et al., 2002; Hofmann et al., 2002) , Hdm21 (Le et al., 1996) , Chk2 (Yang et al., 2002; Louria-Hayon et al., 2003) , hSir2 (Langley et al., 2002) and herpesvirusassociated ubiquitin-specific protease (HAUSP) (Everett et al., 1997; Li et al., 2002) . Intact PML bodies are needed for genotoxic stress-induced p53-dependent apoptosis. Upon high-dose UV-irradiation, HIPK2 localizes together with PML, p53 and the acetyltransferase CBP in the PML-NBs (D'Orazi et al., 2002; Hofmann et al., 2002) . HIPK2 directly interacts with and phosphorylates p53 at Ser 46, thus facilitating the CBP-mediated acetylation of p53 at Lys 382, and increasing the cellular susceptibility to p53-mediated apoptosis.
To investigate the molecular mechanism behind PRIMA-1-induced apoptosis, we monitored the changes in subcellular localization of mutant p53 and p53-related proteins in tumor cells upon PRIMA-1 MET -treatment. We found that mutant p53 and the PML-NB-associated proteins PML, Hsp70 and CBP were redistributed to the nucleoli in PRIMA-1 MET -treated cells.
Results

PRIMA-1 and PRIMA-1
MET induces nucleolar accumulation of mutant p53 In order to study how PRIMA-1 MET affects the cellular localization of mutant p53, we treated human tumor cells with PRIMA-1 MET and examined the intracellular distribution of p53 by immunostaining. We examined p53 localization in H1299-His175 (exogenous mutant p53) cells and SW480 (endogenous mutant p53) cells cultured in the presence of PRIMA-1 MET for 16 h. We found that treatment with PRIMA-1 MET induced p53 nucleolar accumulation in 79.8% of the H1299-His175 cells and 33.7% in the SW480 cells ( Figure 1A and B). At later time points the fraction of p53-positive cells that showed mutant p53 redistribution to nucleoli was even higher ( Figure 1C ). These cell lines were more sensitive to PRIMA-1 MET -induced apoptosis compared to the p53 null cells (data not shown). Double-staining for p53 and B23 (nucleophosmin) verified nucleolar localization of p53 ( Figure 1D ). Treatment of H1299-His175 with the original PRIMA-1 also induced nucleolar accumulation of mutant p53, although to a lesser extent than PRIMA-1 MET (Figure 2A and B). Interestingly, treatment of H1299-His175 cells with PRIMA-Dead, a compound that is structurally related to PRIMA-1 but inactive with regard to induction of mutant p53-dependent apoptosis, did not induce nucleolar translocation of p53 (Figure 2A-C 
PRIMA-1
MET causes redistribution of the PML-associated proteins PML and CBP The PML nuclear bodies might be involved in regulating apoptosis by serving as modification or activation platforms for p53 and by controlling the subcellular availability of p53 and other apoptotic proteins. We studied the nuclear distribution of the PML-NBassociated protein PML in response to PRIMA-1 MET -treatment and found that PML ( Figure 3A and B) localized to the nucleoli in PRIMA-1 MET -treated H1299-His175 cells but not in control-treated cells. PRIMA-1 MET -induced nucleolar accumulation of PML was enhanced, but not dependent, on the presence of mutant p53 ( Figure 3A and B). Nucleolar accumulation of PML was also observed in PRIMA-1 MET -treated SW480 cells ( Figure 3A and B). Moreover, the PML-NB-associated protein CBP was also found to target the nucleoli in H1299-His175 cells upon treatment with PRIMA-1 MET ( Figure 4A and B). Presence of mutant p53 was important for the PRIMA-1 MET -induced nucleolar accumulation of CBP since only a few exceptional cases of nucleolar CBP was seen in H1299 cells upon treatment with PRIMA-1 MET ( Figure 4A and B). As CBP mediates acetylation of p53 at Lys 382 we examined if treatment with PRIMA-1 MET induced the levels of acetylated p53. However, we did not detect any increased p53 acetylation (Lys382) after 16 h of PRIMA-1 MET -treatment of H1299-His175 cells (data not shown).
PRIMA-1 MET induces Hsp70 expression and accumulation in nucleoli
The stress response protein Hsp70 is often redistributed to the nucleus and the nucleolus during stress. We found that Hsp70 localized to the nucleoli upon treatment with PRIMA-1 MET . This was strongly enhanced by the presence of mutant p53 since almost no nucleolar Hsp70 accumulation was observed in p53-null H1299 cells ( Figure 5A and B). As we observed a higher intensity of the Hsp70 staining in PRIMA-1 MET -treated H1299, H1299-His175 and SW480 cells ( Figure 5C ), we also examined Hsp70 protein levels by Western blot analysis. Treatment of cells with PRIMA-1 MET for 16 h caused an increase in Hsp70 protein levels in H1299-His175 and SW480 by a factor of 2.8 and 2.4, PRIMA-1MET induces nucleolar accumulation of mutant p53 N Rökaeus et al respectively, according to quantification by densitometry ( Figure 5D ). Treatment of H1299-His175 cells with the inactive PRIMA analog PRIMA-Dead did not cause any change in the cellular distribution of Hsp70 ( Figure 6A ) nor any increase in Hsp70 staining intensity ( Figure 6B ). PRIMA-1MET induces nucleolar accumulation of mutant p53 N Rökaeus et al
Discussion
The low molecular weight compound PRIMA-1 was identified in a cellular screen for molecules that induce apoptosis in human tumor cells in a mutant p53-dependent manner (Bykov et al., 2002a, b) . PRIMA-1 restores wild-type conformation and DNA binding to mutant p53 proteins, causes upregulation of p53 target genes such as p21, MDM2 and PUMA, and inhibits growth of human tumor xenografts in vivo upon systemic treatment. PRIMA-1 MET , a methylated form of PRIMA-1, is even more potent in inducing mutant p53-dependent apoptosis than PRIMA-1 itself (Bykov et al., 2005b) . The exact molecular mechanism for mutant p53 reactivation by PRIMA-1 has not been elucidated. Here, we have examined the intracellular distribution of mutant p53 and several other PML-NBassociated proteins in cells treated with PRIMA-1 or PRIMA-1 MET . We have found that mutant p53, PML, Hsp70 and CBP are redistributed to the nucleoli upon PRIMA-1 MET treatment. The redistribution of PML, CBP and Hsp70 is enhanced in the presence of mutant p53. Interestingly, the non-PML-NB-associated protein p300 did not change its cellular localization after treatment with PRIMA-1 MET . Moreover, when we treated cells with PRIMA-Dead, a PRIMA-1 structural analog lacking the mutant p53-dependent apoptosisinducing properties, no nucleolar accumulation of mutant p53, Hsp70 or PML was observed, even at higher concentrations. Induction of apoptosis with other agents, for example, cisplatin or the mutant p53-reactivating compound MIRA-1, did not result in PRIMA-1MET induces nucleolar accumulation of mutant p53 N Rökaeus et al nucleolar accumulation of mutant p53. This indicates that nucleolar accumulation of mutant p53 is not a general response to apoptosis-inducing and/or mutant p53-reactivating compounds, but a specific effect of PRIMA-1 MET treatment. Other apoptosis-inducing agents, for example, the topoisomerase inhibitor doxorubicin, have been shown to cause nucleolar accumulation of PML and MDM2 but not p53 (Bernardi et al., 2004) . However, we did not observe any increased nucleolar accumulation of MDM2 in PRIMA-1 MET -treated SW480 cells. Accumulation of mutant p53, Hsp70, PML and EBVencoded EBNA-5 in the nucleoli has been observed in cells upon treatment with the proteasome inhibitor MG132 Pokrovskaja et al., 2001 ). However, PRIMA-1 MET did not inhibit proteasomal degradation of a reporter substrate in a human melanoma cell line (Victoria Mene´ndez-Benito and Nico Dantuma; Karolinska Institute, Stockholm, Sweden, unpublished results), suggesting that the observed nucleolar accumulation of mutant p53 is not due to inhibition of the proteasome.
The nucleolus is a plurifunctional, nuclear organelle organized around the repeated ribosomal gene clusters. Its major function is to synthesize rRNA and assemble ribosomal subunits (for a review, see Olson and Dundr (2005) ). However, recent findings show that factors not obviously connected with ribosome biogenesis are present in the nucleoli, including viral proteins, polyadenylated mRNAs, cell-cycle regulatory and tumorrelated proteins, suggesting its involvement in a wide range of cellular processes, such as RNA processing, cell-cycle regulation, control of aging, modulation of telomerase function, viral replication and tumor suppression (for reviews, see Ruggero and Pandolfi (2003) ; Olson and Dundr (2005) ). A novel role for the nucleolus is its participation in the regulation of the tumor-suppressor p53. It has been proposed that the nucleolus also function as a major cellular stress sensor and transmits signals to the system for regulation of p53 activity (Rubbi and Milner, 2003) . Localization of proteins within specific subcellular compartments is an additional route for modulating protein functions. Nucleolar sequestration has been reported to regulate protein activity (Tao and Levine, 1999; Visintin et al., 1999) One possibility is that PRIMA-1 MET affects ribosomal biogenesis by inducing accumulation of mutant p53 and other proteins in the nucleoli. Studies by Arabi et al. (2003 Arabi et al. ( , 2005 , have shown that excess c-Myc can accumulate within nucleoli and activate Pol I transcription in the absence of Pol II transcription, suggesting that c-Myc drives cell growth by stimulating ribosome biogenesis. In contrast, wild-type p53 can suppress Pol I transcription by directly interfering with the assembly of a protein complex that is essential for transcriptional initiation on the rRNA promoter (Zhai and Comai, 2000) . Wild-type p53 has also been shown to repress RNA polymerase III (Pol III) transcription (Cairns and White, 1998) . It is conceivable that deregulation of Pol I and Pol III activity in mutant p53-harboring cancer cells could contribute to tumorigenesis. If so, Pol I and/or Pol III could represent targets for novel cancer therapy. Thus, it should be addressed if PRIMA-1 MET affects tumor cell viability by inhibiting ribosome biogenesis and protein synthesis through nucleolar translocation of reactivated mutant p53.
The Hsp70 family of chaperones assists cellular proteins in many processes, including folding, transport through membranes, degradation and escape from aggregation. Many pharmacological compounds have been shown to induce a heat shock protein response characterized by increased expression of stress proteins that provide cellular protection via increased chaperoning activity (Pespeni et al., 2005) . We found that the level of Hsp70 was significantly increased in H1299-His175 and SW480 cells upon treatment with PRIMA-1 MET and that both Hsp70 and mutant p53 accumulated in the nucleoli. This indicates that PRIMA-1 MET treatment induces a heat shock response in cells, and also raises the possibility that Hsp70 may play a role in mutant p53 refolding by PRIMA-1 MET . In agreement with this idea, the inactive PRIMA-analog PRIMADead did not affect the distribution or the level of Hsp70. It is also noteworthy that a recent study has implicated Hsp90 in PRIMA-1-mediated mutant p53 reactivation (Rehman et al., 2005) . However, although both Hsp70 and p53 translocate to the nucleolus, they are localized to different subnucleolar compartments. Further studies are needed to elucidate the role of Hsp70 in mutant p53 reactivation by PRIMA-1. In conclusion, our data indicate that redistribution of mutant p53 to nucleoli, and/or redistribution of other PML bodyassociated proteins, may play an important role for mutant p53 reactivation and induction of tumor cell apoptosis by PRIMA-1 MET .
Materials and methods
Cells and cell culture Cells used in this study were the human lung adenocarcinoma line H1299 (p53-null) and a subline carrying tet-regulated (Tet-Off) 
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N Rökaeus et al His175 mutant p53, the human colon carcinoma line SW480 (endogenous His273 mutant p53), the breast carcinoma cell line MCF-7 (endogenous wild-type p53), and the osteosarcoma cell line U2OS (endogenous wild-type p53). Cells were grown at 371C with 5% CO 2 in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum, 2 mM L-glutamine, 40 mg/ml gentamicin. 
PRIMA-treatment and immunofluorescence staining
The cells were placed on cover slips in six-well plates at an initial density of 8 Â 10 3 cells/cm 2 . Next day cells were incubated for 16 h in the presence of 25-50 mM PRIMA-1 MET , 25-50 mM PRIMA-1, 25-100 mM PRIMA-Dead, 8-25 mM MIRA or 2 mg/ml Cisplatin. All compounds except cisplatin were dissolved in dimethylsulphoxide (DMSO). Cells treated with DMSO were used as controls. Cells were fixed with methanol-acetone (1:1) at À201C for 15 min and then rehydrated in phosphate-buffered saline (PBS) for 20 min. Antibodies were diluted in blocking buffer (2% bovine serum albumin, 0.2% Tween-20, 10% glycerol in PBS). Cells were incubated with the primary antibody in a moist chamber for 40 min at room temperature and then washed three times with PBS. Thereafter incubation with secondary antibody for 30 min at room temperature followed by three PBS washes. The double stainings were performed as follows: primary mouse antibody/secondary anti-mouse/normal mouse serum/primary rabbit antibody/secondary anti-rabbit. DNA was stained by Hoechst 33258 or 4,6-diamidino-2-phenylindole (DAPI). The cover slips were mounted with Vectashield mounting medium or Vectashield hardset mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Images were collected using a Zeiss Axioplan 2 microscope, equipped with an AxioCam HRm Camera. The software used was Axio Vision 4.2. For quantitative data, a minimum of 500 cells were analysed. PRIMA-1MET induces nucleolar accumulation of mutant p53 N Rökaeus et al
Western blotting
